(Reuters) -Paracetamol maker Granules India reported a 34% jump in its second-quarter profit on Thursday, driven by strong demand in its key European and North American markets.
Consolidated profit rose to 1.31 billion rupees (nearly $15 million) in the quarter ended September 30 from 972.3 million rupees a year earlier.
Granules, which generates about two-thirds of its revenue from North America and 19% from Europe, posted a 34.2% rise in revenue from operations to 12.97 billion rupees.
Sales in North America jumped 30%, while those in Europe surged 66%.
For further earnings highlights, click.
KEY CONTEXT
Granules India, which has a 30% share of the global paracetamol market, supplies the drug both as an active pharmaceutical ingredient (API) and in finished dosage form across Europe, Canada, and South Africa.
APIs are the core components in medicines responsible for their therapeutic effects.
Indian API manufacturers, including Granules, are facing pricing pressures in key Western markets like Europe and North America due to intensifying competition.
This comes even as global pharmaceutical companies increasingly turn to India to diversify their supply chains and reduce dependence on Chinese API suppliers.
PEER COMPARISON
Estimates (next
12 months) Analysts’ sentiment
RIC PE EV/EBI Revenue Profit Mean # of Stock to Div
TDA Growth Growth rating analyst price target yield
(%) (%) s (%)
Granules India Ltd 20.11 11.45 13.32 22.64 STRONG 4 0.98 0.28
BUY
Laurus Labs Ltd 62.89 30.00 17.20 47.48 HOLD 13 1.11 0.16
Alivus Life Sciences Ltd 19.19 12.56 11.24 17.92 STRONG 4 0.75 0.55
BUY
Divi’s Laboratories Ltd 59.21 41.98 16.34 21.95 HOLD 26 0.97 0.46
* Mean of analysts’ ratings standardised to a scale of Strong Buy, Buy, Hold, Sell, and Strong Sell** Ratio of the stock’s last close to analysts’ mean price target; a ratio above 1 means the stock is trading above the PT
JULY TO SEPTEMBER STOCK PERFORMANCE
— All data from LSEG
— $1 = 87.8950 Indian rupees
(Reporting by Kashish Tandon in Bengaluru; Editing by Subhranshu Sahu)
Comments